| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology Section, Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892
Osteogenic sarcoma is the most common bone tumor of childhood and typically occurs during the adolescent growth spurt when growth hormone and insulin-like growth factor I (IGF-I) may be at their lifetime highest levels. Since IGF-I is involved in normal bone growth and differentiation, we have evaluated the possible role of IGF-I signaling in the growth of human osteogenic sarcoma cell lines. In this study, we demonstrate that in vitro survival of cells is dependent on exogenously supplied IGF-I. Furthermore, we show that these cells display functional IGF-I receptors on their surface and that in vitro growth is inhibited by blocking these receptors either by monoclonal antibodies or by antisense oligonucleotides. These data demonstrate that human osteogenic sarcoma cell lines are dependent on signaling through the IGF-I receptor for in vitro survival and proliferation. Furthermore, they suggest that modulation of the growth hormone/IGF-I axis may affect the growth of these tumors in vivo.
1 To whom requests for reprints should be addressed, at Molecular Oncology Section, Pediatric Branch, National Cancer Institute, Building 10/13N240, Bethesda, MD 20892.
Received 12/13/93. Accepted 3/15/94.
This article has been cited by other articles:
|
|
 |
|
  Z. Duan, E. Choy, D. Harmon, C. Yang, K. Ryu, J. Schwab, H. Mankin, and F. J. Hornicek Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines Mol. Cancer Ther., August 1, 2009; 8(8): 2122 - 2130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Avnet, L. Sciacca, M. Salerno, G. Gancitano, M. F. Cassarino, A. Longhi, M. Zakikhani, J. M. Carboni, M. Gottardis, A. Giunti, et al. Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma Cancer Res., March 15, 2009; 69(6): 2443 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Kim, J. A. Toretsky, D. Scher, and L. J. Helman The Role of IGF-1R in Pediatric Malignancies Oncologist, January 1, 2009; 14(1): 83 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Savage, K. Woodson, E. Walk, W. Modi, J. Liao, C. Douglass, R. N. Hoover, S. J. Chanock, and The National Osteosarcoma Etiology Study Group Analysis of Genes Critical for Growth Regulation Identifies Insulin-like Growth Factor 2 Receptor Variations with Possible Functional Significance as Risk Factors for Osteosarcoma Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1667 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Spence, A. L. Shaffer, L. M. Staudt, S. Amde, S. Manney, C. Terry, K. Weisz, and P. Nissley Transformation of Late Passage Insulin-Like Growth Factor-I Receptor Null Mouse Embryo Fibroblasts by SV40 T Antigen. Cancer Res., April 15, 2006; 66(8): 4233 - 4239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Maloney, J. L. McLaughlin, N. E. Dagdigian, L. M. Garrett, K. M. Connors, X.-M. Zhou, W. A. Blattler, T. Chittenden, and R. Singh An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation Cancer Res., August 15, 2003; 63(16): 5073 - 5083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Sklar, A. C. Mertens, P. Mitby, G. Occhiogrosso, J. Qin, G. Heller, Y. Yasui, and L. L. Robison Risk of Disease Recurrence and Second Neoplasms in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3136 - 3141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Khanna, J. Prehn, D. Hayden, R. D. Cassaday, J. Caylor, S. Jacob, S. M. Bose, S.-H. Hong, S. M. Hewitt, and L. J. Helman A Randomized Controlled Trial of Octreotide Pamoate Long-acting Release and Carboplatin versus Carboplatin Alone in Dogs with Naturally Occurring Osteosarcoma: Evaluation of Insulin-like Growth Factor Suppression and Chemotherapy Clin. Cancer Res., July 1, 2002; 8(7): 2406 - 2412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Carter, M. M. Ramsey, R. L. Ingram, A. B. Cashion, W. T. Cefalu, Z.Q. Wang, and W. E. Sonntag Models of Growth Hormone and IGF-1 Deficiency: Applications to Studies of Aging Processes and Life-Span Determination J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2002; 57(5): B177 - 188. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski Acute Lymphoblastic Leukemia Hematology, January 1, 2002; 2002(1): 162 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text]
|
|
|
|
 |
|
 A Bavelloni, S Santi, A Sirri, M Riccio, I Faenza, N Zini, S Cecchi, A Ferri, P Auron, N. Maraldi, et al. Phosphatidylinositol 3-kinase translocation to the nucleus is induced by interleukin 1 and prevented by mutation of interleukin 1 receptor in human osteosarcoma Saos-2 cells J. Cell Sci., January 3, 1999; 112(5): 631 - 640. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
